Guidant Announces U.S. Approval for Advanced Rhythm Discrimination Implantable Defibrillator

by Michael Johns, Project Manager | April 07, 2004

The VITALITY 2 system incorporates Guidant's proprietary RHYTHM ID^TM feature, which utilizes rhythm discrimination technology, is designed to distinguish lethal from non-lethal heart rhythms and deliver the appropriate care at the appropriate time.

"Guidant is committed to treatment options that enable physicians to provide optimal therapy for their patients at risk for sudden cardiac death," said Fred McCoy, president, Cardiac Rhythm Management, Guidant Corporation. "The launch of the VITALITY 2 represents an important step forward in our ongoing efforts to help these people live longer."

Full market launch of the VITALITY 2 implantable defibrillator is scheduled for May 2004.

Ensure critical devices are ready to go

Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.